Factors influencing hepatic metabolism of antihypertensive drugs: impact on clinical response
| Autor: | Julieta Sofía del Mauro, Facundo Martín Bertera, Yanina Santander Plantamura, Christian Höcht, Luciano Parola, Ariel H. Polizio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
PHARMACOKINETICS
Farmacología y Farmacia CIENCIAS MÉDICAS Y DE LA SALUD Genotype Adrenergic beta-Antagonists Blood Pressure Pharmacology METABOLISM Toxicology 030226 pharmacology & pharmacy CALCIUM CHANNEL BLOCKERS Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Pharmacokinetics ANGIOTENSIN RECEPTOR BLOCKERS Humans Medicine Antihypertensive Agents Β-BLOCKERS Dose-Response Relationship Drug biology PHARMACOGENETICS business.industry Calcium channel Angiotensin-converting enzyme General Medicine Metabolism Calcium Channel Blockers Medicina Básica Blood pressure 030220 oncology & carcinogenesis Hypertension biology.protein Angiotensin Receptor Blockers business Pharmacogenetics Drug metabolism |
| Popis: | Introduction: Although main antihypertensive drugs are able to efficiently reduce blood pressure, only a third of treated hypertensive patients achieve optimal blood pressure control. Extensive interpatient variability on drug metabolism and oral disposition of blood pressure lowering drugs can contribute to this failure in hypertension management. Areas covered: The aim of the present review is to update the knowledge on the features of hepatic metabolism of the main antihypertensive agents, including β-blockers, calcium channel blockers, angiotensin receptor blockers, and angiotensin converting enzyme inhibitors. The factors that contribute to the large interindividual variability of main antihypertensive drugs are also covered. Expert opinion: The variability of plasma concentration of antihypertensive drugs due to the involvement of hepatic metabolism can contribute to the inadequate control of blood pressure in the daily clinical practice. Genotype screening of specific hepatic drug-metabolizing enzymes may contribute to optimize dose selection and to increase the rate of blood pressure control in patients treated with specific β-blockers, calcium channel blockers, and angiotensin receptor blockers. Fil: Höcht, Christian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina Fil: Bertera, Facundo Martin. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina Fil: Santander Plantamura, Yanina Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina Fil: Parola, Luciano. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina Fil: del Mauro, Julieta Sofía. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina Fil: Polizio, Ariel Héctor. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|